Skip to content

Glucocorticoids and Pulmonary Hypertension

Prospective Study of Glucocorticoids as a Mechanism to Treat Pulmonary Hypertension

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04499196
Enrollment
40
Registered
2020-08-05
Start date
2020-07-29
Completion date
2022-07-29
Last updated
2022-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchopulmonary Dysplasia, Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases and Hypoxia

Brief summary

Pediatric idiopathic pulmonary hypertension has significant morbidity and mortality. An ever expanding body of knowledge indicates the important contribution of inflammation to pathogenesis and successful treatment with glucocorticoids. Over the last several years the investigators have utilized steroids in patients with severe pulmonary hypertension as part of a treatment regimen. These basic science studies possibly identifies a biochemical etiology for the development of disease and may also be impacted by the administration of steroids. Additionally, there is a commercially available assay which tests for all of the above molecules.

Interventions

DRUGGlucoCorticoid

Administering glucocorticoid

Sponsors

Washington University School of Medicine
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Days to 5 Years
Healthy volunteers
No

Inclusion criteria

* premature, BPD, \>36 wga * pulmonary hypertension evidence by echocardiogram

Exclusion criteria

* poor ventilation/oxygenation

Design outcomes

Primary

MeasureTime frame
Echo estimation of RV pressure5 days

Countries

United States

Contacts

Primary ContactManish Aggarwal, MD
maggarwal@wustl.edu314-273-8329
Backup ContactRonald M Grady, MD
rmgrady@wustl.edu314-454-6095

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026